{"entity":{"id":"nct07562503","kind":"trial","name":"Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","aka":["CLEAR-03"],"tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Fudan University, now recruiting.","summary":"Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07562503 by Fudan University, with a registry enrolment figure of 340 participants, started 2024-11-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: CAPEOX regimen; CAPEOX regimen. Conditions listed: ctDNA; Colorectal Cancer; Chemotherapy. Primary outcome: Patient's 2-year Progression-Free Survival. Colorectal eligibility wording from the registry: \"Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07562503","url":"https://clinicaltrials.gov/study/NCT07562503"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","mrd-testing","platinum"],"targets":[],"drugs":["capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07562503","phase":"2","setting":"Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","sponsor":"Fudan University","enrolled":340,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07562503/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}